YY-201
- Generic Name
- YY-201
An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies
- First Posted Date
- 2024-01-26
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Shanghai Yuyao Biotech Co., Ltd.
- Target Recruit Count
- 96
- Registration Number
- NCT06225856
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
Pharmacokinetics and Safety/Tolerability of YY-201 in Comparison to Dutasteride and Tadalafil
Phase 1
Completed
- Conditions
- Benign Prostatic Hyperplasia
- Interventions
- First Posted Date
- 2017-08-07
- Last Posted Date
- 2017-11-24
- Lead Sponsor
- Yuyu Pharma, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT03240939
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath